In this article, we will discuss the 10 Best NASDAQ Growth Stocks to Buy and Hold Forever.
On April 15, Kim Bolton, President & Portfolio Manager at Black Swan Dexteritas, appeared on BNN Bloomberg to share his outlook on Technology Stocks. Talking about how the Iran conflict over the last six weeks impacted the market’s trajectory, Bolton suggested that the market serves as a future predictor and has effectively pushed those concerns aside. He observed that investors seem to view the conflict as being in the rear-view mirror, shifting their focus back toward earnings season and the AI bandwagon. While tech lagged for much of the year, Fernandez notes that Nvidia recently climbed back toward the $200 mark, which it had not reached in a long time.
Bolton addressed the recent lagging of the tech sector by clarifying that he does not see a general rotation from growth into value. Instead, he believes that there has been a specific rotation within the tech industry. Investors have taken profits from pick-and-shovel companies (those building the AI infrastructure) and reallocated that capital into end-users who are successfully employing and embedding AI into their operations. He pointed out that this shift is already yielding results in the financial sector, where big US banks are reporting increased productivity and revenue generation from AI. He also sees this maturing AI stack benefiting healthcare, retail, and logistics.
Our Methodology
We used screeners to identify stocks that have a track record of delivering earnings growth and have grown their EPS by at least 20% over the past 3 years, and are expected to grow their earnings by at least 25% over the next 5 years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on April 23.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best NASDAQ Growth Stocks to Buy and Hold Forever
10. HeartBeam Inc. (NASDAQ:BEAT)
HeartBeam Inc. (NASDAQ:BEAT) is one of the best NASDAQ growth stocks to buy and hold forever. On April 14, HeartBeam announced the pricing of a $10 million underwritten public offering, consisting of 12,500,000 shares of common stock. The offering is notably led by the company’s first commercial customer, ClearCardio, alongside HeartBeam’s executive leadership, board members, and existing institutional investors. Underwriters have also been granted a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments.
The company plans to use the net proceeds to fund several key strategic initiatives, including the commercialization of its FDA-cleared 12-lead synthesized ECG system. Additionally, the capital will support the development of an extended-wear patch, heart attack detection technology, and the enhancement of HeartBeam’s AI capabilities. These efforts are aimed at expanding the reach of the company’s cardiac monitoring platform and providing more accessible insights for patients and providers.
CEO Robert Eno emphasized that the participation of ClearCardio as an investor serves as a validation of HeartBeam Inc.’s (NASDAQ:BEAT) technology, particularly within the preventive cardiology and concierge healthcare markets. The financing provides the necessary working capital to support general corporate purposes and meet the growing demand for data-driven cardiac care.
HeartBeam Inc. (NASDAQ:BEAT) is a medical technology company specializing in 3D, credit-card-sized ECG solutions for remote cardiac monitoring. Its HeartBeam System enables high-fidelity arrhythmia and heart attack detection outside of clinical settings using portable hardware and cloud-based algorithms.
9. Cingulate Inc. (NASDAQ:CING)
Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the recent acceptance of an NDA for its lead ADHD candidate, CTx-1301. The company also announced a strengthened intellectual property portfolio, including a US Patent Notice of Allowance and additional grants in Europe for CTx-1301. These legal milestones recognize the unique capabilities of Cingulate’s proprietary Precision Timed Release/PTR platform, which is designed to deliver medication according to specific patient needs throughout the day.
Furthermore, the company recently closed a $12 million private placement at-the-market pricing to support its foundation. The CEO noted that this funding, combined with the addition of experienced commercial leadership, supports the company’s transition toward market readiness. While advancing through the FDA regulatory review process for CTx-1301, Cingulate is focusing on manufacturing scale-up to ensure it is positioned for a successful commercial launch upon potential approval.
The company’s strategy remains centered on using its PTR platform to develop a pipeline of next-gen products that address unmet needs in the biopharma space. The CEO emphasized that the progress made throughout 2025 has set a strong trajectory for 2026, with a focus on building long-term value for shareholders and patients alike. By securing its patent estate and strengthening its balance sheet, Cingulate Inc. (NASDAQ:CING) aims to provide a different treatment option for the ADHD market.
Cingulate Inc. (NASDAQ:CING) is a clinical-stage biotech company using its proprietary drug delivery platform to develop treatments for ADHD and anxiety. Its lead candidate, CTx-1301, is in Phase 3 trials for ADHD across all age groups, while its pipeline includes CTx-2103 for anxiety and plans for CTx-1302 to further address ADHD.
8. iBio Inc. (NASDAQ:IBIO)
iBio Inc. (NASDAQ:IBIO) is one of the best NASDAQ growth stocks to buy and hold forever. On April 8, iBio received regulatory clearance and ethics approval to initiate its first-in-human Phase 1 clinical trial of IBIO-600 in Australia. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of the therapy in overweight and obese participants. The company expects to dose the first participants in Q2 2026, marking iBio’s transition into a clinical-stage biotechnology firm.
IBIO-600 is a long-acting monoclonal antibody designed to target myostatin and GDF11, which are negative regulators of muscle growth. By inhibiting these proteins, the therapy aims to preserve lean muscle mass and improve overall body composition, specifically addressing the muscle loss often associated with GLP-1 weight-loss treatments. Engineered for infrequent administration, the drug has the potential for a dosing schedule of only two to four times per year.
The advancement into clinical trials follows preclinical studies in non-human primates that showed a significant half-life of up to 52 days and increases in lean mass of up to 5.1% after a single dose. CEO Martin Brenner noted that the rapid move from program initiation to the clinic in just two years highlights the efficiency of the company’s AI-integrated discovery platform. IBIO-600 is positioned as a potentially best-in-class solution to fill critical gaps in the current obesity treatment landscape.
iBio Inc. (NASDAQ:IBIO) is a biotech company that uses its patented AI drug discovery platform and advanced computational biology to develop next-gen biopharmaceuticals. The company is focused on creating novel therapies for obesity, cardiometabolic disorders, cancer, and other hard-to-treat diseases.
7. Invivyd Inc. (NASDAQ:IVVD)
Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ growth stocks to buy and hold forever. On April 9, Invivyd announced significant progress in its REVOLUTION clinical program, specifically regarding VYD2311, a monoclonal antibody candidate for COVID-19 prevention. A pre-specified analysis of the Phase 3 DECLARATION study revealed that accumulated clinical events already provide sufficient statistical power to support high-end efficacy targets.
Consequently, Invivyd has triggered a conservative upsizing of the study by ~500 subjects to ensure robust data across various scenarios. This adjustment is expected to shift the timing of top-line results slightly, moving from mid-year guidance to Q3 2026. In addition to its COVID-19 efforts, the company revealed the discovery and advancement of VMS063, a novel monoclonal antibody for the treatment and prevention of measles.
Designed to be a first-in-class precision therapy, VMS063 targets the measles Fusion protein to prevent cell entry, demonstrating high potency against circulating lineages in laboratory assays. With US measles incidence reaching decade-high levels, Invivyd Inc. (NASDAQ:IVVD) is fast-tracking VMS063 toward regulatory outreach and IND-enabling studies, with a target for IND readiness in late 2026.
Invivyd Inc. (NASDAQ:IVVD) develops next‑generation antibody drugs aimed at long‑lasting effectiveness against evolving viruses, using a proprietary platform to deliver durable therapies.
6. Eton Pharmaceuticals Inc. (NASDAQ:ETON)
Eton Pharmaceuticals Inc. (NASDAQ:ETON) is one of the best NASDAQ growth stocks to buy and hold forever. On April 16, Eton Pharmaceuticals announced a succession plan for its Chief Financial Officer, appointing Judith M. Matthews as Executive Vice President of Accounting and Finance. Matthews is scheduled to officially assume the CFO role on June 1, succeeding James Gruber. To facilitate a smooth leadership transition, Gruber will remain in his current position through May 31 and has committed to a subsequent six-month consulting agreement with the company.
Matthews joins the organization with over 25 years of experience in financial leadership within the pharmaceutical and biotechnology sectors. She most recently served as the CFO of Iterum Therapeutics from 2015 to 2026 and previously held the role of Vice President of Finance at Durata Therapeutics.
CEO Sean Brynjelsen noted that Matthews’ expertise in managing growth-focused companies will be vital as Eton enters its next developmental phase. The company remains focused on its mission to build the largest rare disease portfolio in the US through product integrations and rapid expansion. Matthews expressed enthusiasm for the company’s unique business model and its pivotal position in the industry as she prepares to partner with the executive team on long-term strategic goals.
Eton Pharmaceuticals Inc. (NASDAQ:ETON) is a healthcare company dedicated to developing and commercializing treatments for rare diseases. Its portfolio includes products for conditions like adrenal insufficiency and Wilson disease, alongside a robust pipeline of late-stage candidates such as ET-600 and the ZENEO hydrocortisone autoinjector.
While we acknowledge the potential of ETON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ETON and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best NASDAQ Growth Stocks to Buy and Hold Forever.
Disclosure: None. None. Follow Insider Monkey on Google News.
